In a significant move for dermatology care in the country, Mumbai-headquartered pharmaceutical giant Sun Pharma has officially launched its globally recognized innovative biologic, Ilumya (Tildrakizumab), in the Indian market. This therapy is specifically designed for the treatment of moderate-to-severe plaque psoriasis, marking a pivotal expansion of the company's specialty portfolio within India.
A Global Therapy Arrives in India
Ilumya is a patented biologic therapy that was first introduced in the United States approximately six years ago. Since then, its reach has expanded to 35 countries worldwide. According to a company statement, the drug has gained international recognition for its ability to provide long-lasting skin clearance, coupled with a strong safety profile and a minimal burden of monitoring for patients.
Robust Clinical Data from Indian Patients
The launch in India is supported by compelling Phase-3 clinical trial data generated within the country. The study involved 115 Indian patients, providing robust evidence for the local population. The therapy demonstrated high efficacy, with a significant number of patients achieving PASI-75 and PASI-90 response rates as early as the 12th week of treatment.
These improvements were not just rapid but also sustained, continuing through the 28-week study period. PASI scores are a standard measure used to assess the severity and extent of psoriasis, making these results particularly noteworthy for dermatologists and patients seeking effective, long-term management solutions.
Addressing an Unmet Medical Need
Sun Pharma's leadership has underscored this launch as a major step toward filling a critical gap in psoriasis care in India. The introduction of Ilumya provides a new, targeted, and durable treatment option for a condition that often requires long-term management.
Moderate-to-severe plaque psoriasis can significantly impact a patient's quality of life, and the availability of advanced biologics like Tildrakizumab offers hope for better disease control with a favorable safety outlook. This move aligns with the growing need for specialized, innovative therapies in the Indian healthcare landscape.
